Women Can Now Get The Abortion Pill Through The Mail
(Interjection – It should be obvious by now — after reading “When is a Human, Human?” and other such articles — that this website/church is in FULL agreement with a woman’s God-given free-will choice. Her right to terminate an unwanted pregnancy that could, because of governmental “representative” limitations on aid after a forced and often unwanted birth, often keep her poverty-laden for many years. We’re grateful that woman can now get the abortion pill through the mail. However, a pandemic simply SHOULDN’T have been needed to help effect such a ruling!!! ~ Don Chapin)
In a victory for reproductive rights, many patients seeking medication abortion will no longer have to travel during the pandemic for care.
By Melissa Jeltsen, 07/13/2020 07:01 pm ET
For the first time ever, U.S. women seeking to terminate a pregnancy using medication abortion will be able to legally obtain the abortion pill through the mail, avoiding the need for an in-person doctor’s visit.
A federal court ruled on Monday that the U.S. Food and Drug Administration must suspend a rule that requires patients to visit a hospital, clinic or medical office to obtain mifepristone, a drug used to terminate pregnancies, during the coronavirus pandemic.
Under existing regulations, patients seeking medication abortion ― a protocol that involves taking mifepristone in combination with a second drug, misoprostol ― must pick up the medicines in person from an abortion clinic, even though the pills are usually swallowed at home. For some patients, this can mean traveling hundreds of miles just to obtain a prescription.
About 40% of all abortions in the U.S. are performed at home using medication abortion. The abortion pill can be taken up to 10 weeks of pregnancy.
Get The Abortion Pill Through The Mail
Monday’s decision allows healthcare providers to send the mifepristone abortion pill through the mail to eligible patients so they don’t have to travel during the pandemic. The ruling comes in response to a lawsuit filed by the American Civil Liberties Union on behalf of a coalition of reproductive rights advocates and medical experts, including more than 60,000 OB-GYNs.
“The In-Person Requirements, combined with the COVID19 pandemic, place a substantial obstacle in the path of women seeking a medication abortion and that may delay or preclude a medication abortion and thus may necessitate a more invasive procedure.” U.S. District Judge Theodore Chuang wrote in the ruling. “Particularly in light of the limited timeframe during which a medication abortion or any abortion must occur, such infringement on the right to an abortion would constitute irreparable harm.”
The in-person dispensing rules will be suspended until at least 30 days after the end of the federal government’s declared public health emergency, Julia Kaye, staff attorney at the ACLU Reproductive Freedom Project, said in an interview.
She noted that the FDA already allowed doctors to prescribe mifepristone using telemedicine. However, women were required to physically pick the drugs up in person. “Now, if a doctor can determine that a patient is eligible for a medication abortion without an additional in-person visit, that patient can stay home during the pandemic and get the medication safely by mail,” she said.
The new rules should go into effect in the next few days, she added.
History and Conclusion
The FDA has come under increasing pressure to change the dispensing rules around mifepristone since the coronavirus outbreak began. In April, Democratic Sens. Elizabeth Warren (Mass.), Patty Murray (Wash.) and Tammy Baldwin (Wis.) sent a letter urging the agency to allow patients to receive the medications without having to go into a health care facility. A coalition of state attorneys general sent a similar letter to the agency at the end of March.
Since its approval in 2000, about 3 million women in the U.S. have used mifepristone. Leading medical groups such as the American College of Obstetricians and Gynecologists (ACOG) advised the FDA to ease restrictions on the drug and make it available in retail pharmacies. A study published in 2019 found that people who received medication abortion by mail had similar outcomes as those who received it at a physician’s office.
“Today’s ruling represents a victory for patients. [Women] should not have to face the additional burden of increased COVID-19 exposure as a condition of receiving their prescribed mifepristone.” said Eva Chalas, president of ACOG. “It also represents a victory for the dedicated clinicians who are working to provide needed care without unnecessary exposure of patients, their families and the members of the healthcare team to the novel coronavirus.”